Mario Sznol, MD

Professor of Medicine (Medical Oncology); Co-Director, Yale SPORE in Skin Cancer

Clinical Interests

  • Medical Oncology
  • Melanoma

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

Cancer Center, Yale: Melanoma Program | Prostate and Urologic Cancers Program

General Urology

Medical Oncology

Yale Medical Group

Office of Cooperative Research

Board Certifications

  • Internal Medicine AB of Internal Medicine (1985)

  • Medical Oncology AB of Internal Medicine (1987)

Clinical Trials

Conditions Study Title
Melanoma, skin S1404: Ph III trial Comparing High Dose Interferon to MK-3475 in Pts w/ High Risk Resected Melanoma
Brain and Nervous System, Lung, Melanoma, skin Pembrolizumab and bevacizumab in untreated brain metastases
Kidney, Lung, Melanoma, skin, Phase I A phase 1/2 Dose escalation and expansion study of NKTR-214 in patients with adv. or met. tumors
Melanoma, skin Study Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 Metastatic Melanoma
Melanoma, skin Refractory B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Exhibits B7-H3 Neoplasms
Colon, Melanoma, skin, Phase I Phase 1 Study of CM-24 (MK-6018) in Subjects with Selected Advanced or Recurrent Malignancies
Kidney, Phase I Phase 1 study of safety & pharmacology with locally advanced or metastatic solid tumors
Melanoma, skin, Phase I Varlilumab and Nivolumab in advanced refractory solid tumors
Soft Tissue, Phase I Phase 1 Study of Mogamulizumab (KW-0761) in Combination with MEDI4736 & Mogamulizumab in Combinati
Lung, Melanoma, skin Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic
Melanoma, skin Stand Up To Cancer
Other Skin Merkel Cell Carcinoma (MCC) Therapy with MK-3475
Melanoma, skin PF-05082566 + MK-3475 IN ADVANCED SOLID TUMORS
Lung, Melanoma, skin Phase 2 Study of MK-3475 in Patients with Melanoma or NSCLC with Untreated Brain Mets
Kidney Active Surveillance of the Small Renal Mass: An Integrated Biomarker Trial
Colon, Kidney, Lung, Other Digestive Organ, Rectum, Stomach, Phase I Phase Ib Trial of MPDL3280A with Bev or with Bev + FOLFOX in Patients with Solid Tumors
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, Thyroid, Phase I PCD4989g: Phase I, Open-label MPDL3280A in solid tumors

Edit this profile

Contact Info

Mario Sznol, MD
Patient Care Location
Smilow Cancer Hospital at Yale-New HavenSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste North Pavilion 8

New Haven, CT 06511
View on map...
Mailing Address
PO Box 208028
333 Cedar Street

New Haven, CT 06520-8028